Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sunesis Pharmaceuticals stock | $1.78

Own Sunesis Pharmaceuticals stock in just a few minutes.

Fact checked

Sunesis Pharmaceuticals, Inc is a biotechnology business based in the US. Sunesis Pharmaceuticals shares (SNSS) are listed on the NASDAQ and all prices are listed in US Dollars. Sunesis Pharmaceuticals employs 24 staff and has a trailing 12-month revenue of around USD$2.2 million.

How to buy shares in Sunesis Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sunesis Pharmaceuticals. Find the stock by name or ticker symbol: SNSS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sunesis Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sunesis Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sunesis Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sunesis Pharmaceuticals share price

Use our graph to track the performance of SNSS stocks over time.

Sunesis Pharmaceuticals shares at a glance

Information last updated 2020-12-03.
Latest market closeUSD$1.78
52-week rangeUSD$1.12 - USD$11.3
50-day moving average USD$1.3211
200-day moving average USD$2.5247
Wall St. target priceUSD$3.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.48

Buy Sunesis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sunesis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sunesis Pharmaceuticals price performance over time

Historical closes compared with the close of $1.78 from 2020-12-09

1 week (2021-01-12) N/A
1 month (2020-12-23) -7.29%
3 months (2020-10-19) N/A
6 months (2020-07-19) N/A
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) N/A
5 years (2016-01-19) N/A

Sunesis Pharmaceuticals financials

Revenue TTM USD$2.2 million
Gross profit TTM USD$2.1 million
Return on assets TTM -39.43%
Return on equity TTM -77.84%
Profit margin 0%
Book value $1.046
Market capitalisation USD$31.1 million

TTM: trailing 12 months

Shorting Sunesis Pharmaceuticals shares

There are currently 607,795 Sunesis Pharmaceuticals shares held short by investors – that's known as Sunesis Pharmaceuticals's "short interest". This figure is 3% up from 589,885 last month.

There are a few different ways that this level of interest in shorting Sunesis Pharmaceuticals shares can be evaluated.

Sunesis Pharmaceuticals's "short interest ratio" (SIR)

Sunesis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Sunesis Pharmaceuticals shares currently shorted divided by the average quantity of Sunesis Pharmaceuticals shares traded daily (recently around 568032.71028037). Sunesis Pharmaceuticals's SIR currently stands at 1.07. In other words for every 100,000 Sunesis Pharmaceuticals shares traded daily on the market, roughly 1070 shares are currently held short.

However Sunesis Pharmaceuticals's short interest can also be evaluated against the total number of Sunesis Pharmaceuticals shares, or, against the total number of tradable Sunesis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sunesis Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Sunesis Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0346% of the tradable shares (for every 100,000 tradable Sunesis Pharmaceuticals shares, roughly 35 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sunesis Pharmaceuticals.

Find out more about how you can short Sunesis Pharmaceuticals stock.

Sunesis Pharmaceuticals share dividends

We're not expecting Sunesis Pharmaceuticals to pay a dividend over the next 12 months.

Have Sunesis Pharmaceuticals's shares ever split?

Sunesis Pharmaceuticals's shares were split on a 1:10 basis on 3 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sunesis Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Sunesis Pharmaceuticals shares which in turn could have impacted Sunesis Pharmaceuticals's share price.

Sunesis Pharmaceuticals share price volatility

Over the last 12 months, Sunesis Pharmaceuticals's shares have ranged in value from as little as $1.12 up to $11.3. A popular way to gauge a stock's volatility is its "beta".

SNSS.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sunesis Pharmaceuticals's is 1.9143. This would suggest that Sunesis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sunesis Pharmaceuticals overview

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site